SCHEMBL2949451

SCHEMBL2949451

CCC(O)Oc1ccc(CN)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 3/20 0.42
ADRA2A P08913 1/20 0.42
APLNR P35414 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
MELK Q14680 1/20 0.38
NFKB1 P19838 1/20 0.38
TAAR1 Q96RJ0 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
TSHR P16473 2/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3639741 0.81 APLNR (0.46) ADRA1AADRA2AAPLNRMELKTAAR1
Methyl Alcohol SCHEMBL28318211 0.79 APLNR (0.59) ADRA1AADRA2AAPLNRTAAR1GAA
SCHEMBL153750 0.78 APLNR (0.63) ADRA1AADRA2AAPLNRTAAR1MAPT
SCHEMBL29350908 0.78 APLNR (0.63) ADRA1AADRA2AAPLNRTAAR1MAPT
Hydrochloric Acid SCHEMBL1197172 0.77 APLNR (0.61) ADRA1AADRA2AAPLNRTAAR1MAPT
SCHEMBL4687675 0.76 TUBB4A (0.47) ADRA1AAPLNRMELKTAAR1MAPT
SCHEMBL2946104 0.76 LMNA (0.45) ADRA1AADRA2AAPLNRMELKTSHR
SCHEMBL701717 0.76 APLNR (0.47) ADRA1AAPLNRTAS1R3TAS1R1MELK
Hydrochloric Acid SCHEMBL5315399 0.75 APLNR (0.59) ADRA1AADRA2AAPLNRMELKTAAR1
SCHEMBL6482266 0.75 APLNR (0.44) ADRA1AADRA2AAPLNRTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750040-B2 G protein-coupled receptor S1P1/EDG1 agonists; low dosage, long lasting immunosuppressive effect; such as 1,1,2-trimethyl-1,1a,5,5a-tetrahydro-3-thia-cyclopropa[a]pentalene-4-carboxylic acid 2,4-dimethoxy-benzylamide ACTELION PHARMACEUTICALS LTD. (CH) 2010-07-06 US disclosed
EP-1805163-B1 1,1A,5,5A-TETRAHYDRO-3-THIA-CYCLOPROPA[A]PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-10-01 EP disclosed
US-20080064740-A1 Novel Thiophene Derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2008-03-13 US disclosed
EP-1805163-A2 1,1A,5,5A-TETRAHYDRO-3-THIA-CYCLOPROPA¬A|PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2007-07-11 EP disclosed
WO-2006010379-A1 NOVEL THIOPHENE DERIVATIVES AS IMMUNOSUPPRESSIVE AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2006-02-02 WO disclosed
WO-2006010544-A2 1, 1A, 5, 5A-TETRAHYDRO-3-THIA-CYCLOPROPA’A! PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064740-A1 Novel Thiophene Derivatives TPMT, TSLP, NFATC1 ADRA1A 3201/4885ADRA2A 3001/4885APLNR 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.